NASDAQ: PCYC       Pharmacyclics Inc
Last Price Today's Change   Day's Range   Trading Volume
0.00   0.00 (0.00%)  0.00 - 0.00  0


Avg Volume (4 weeks):0
Average Price Target: 261.00
Price Target Upside/Downside: +261.00


No recent Headlines for this stock.

Business Background

Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company's commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.

  Be the first to like this.

I3 Messenger
Individual or Group chat with anyone on I3investor

3143  2990  510  3249 

Top 10 Active Counters
 LK 1.38+1.38 
 ADMP 1.879+0.609 
 CTRM 0.409-0.017 
 WPX 9.43+0.48 
 SNDL 0.624-0.037 
 F 11.425-0.105 
 OBLN 6.383+1.193 
 HTZ 0.00-1.75 
 BNGO 9.25+0.98 
 NIO 61.412+3.072